Centessa Pharmaceuticals plc - ADR Forecast, price target & analysts
Centessa Pharmaceuticals plc - ADR Target price 2025 - Analyst rating & recommendation
Centessa Pharmaceuticals plc - ADR Classifications & Recommendation:
Centessa Pharmaceuticals plc - ADR Price Target
| Target Price | $33.66 |
| Price | $26.70 |
| Potential |
26.07%
register free of charge
|
| Number of Estimates | 15 |
|
15 Analysts have issued a price target Centessa Pharmaceuticals plc - ADR 2026 .
The average Centessa Pharmaceuticals plc - ADR target price is $33.66.
This is
26.07%
register free of charge
$42.00
57.30%
register free of charge
$27.27
2.13%
register free of charge
|
|
| A rating was issued by 21 analysts: 20 Analysts recommend Centessa Pharmaceuticals plc - ADR to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Centessa Pharmaceuticals plc - ADR stock has an average upside potential 2026 of
26.07%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.00 | 16.85 |
| 100.00% |
17 Analysts have issued a sales forecast Centessa Pharmaceuticals plc - ADR 2025 . The average Centessa Pharmaceuticals plc - ADR sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Centessa Pharmaceuticals plc - ADR EBITDA forecast 2025. The average Centessa Pharmaceuticals plc - ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
17 Centessa Pharmaceuticals plc - ADR Analysts have issued a net profit forecast 2025. The average Centessa Pharmaceuticals plc - ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.06 | -1.39 |
| 31.21% | 32.52% | |
| P/E | negative | |
| EV/Sales | 170.07 |
17 Analysts have issued a Centessa Pharmaceuticals plc - ADR forecast for earnings per share. The average Centessa Pharmaceuticals plc - ADR EPS is
This results in the following potential growth metrics and future valuations:
Centessa Pharmaceuticals plc - ADR...
Current Centessa Pharmaceuticals plc - ADR Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Wells Fargo |
Locked
➜
Locked
|
Locked | Nov 07 2025 |
| Stephens & Co. |
Locked
➜
Locked
|
Locked | Oct 28 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Oct 06 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Sep 03 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Aug 12 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Jul 30 2025 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Jul 21 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Nov 07 2025 |
|
Locked
Stephens & Co.:
Locked
➜
Locked
|
Oct 28 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Oct 06 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Sep 03 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Aug 12 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Jul 30 2025 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Jul 21 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
